Clinical Trials Directory

Trials / Unknown

UnknownNCT04814589

Bioequivalence of Ezetimibe Tablets in Healthy Subjects

Bioequivalence of Ezetimibe Tablets in Healthy Subjects: A Single-dose and Two-period Crossover Study

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
96 (estimated)
Sponsor
Cao Yu · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

According to the relevant provisions of bioequivalence test, ezetimibe Tablets (test preparation, T, 10mg / tablet) provided by China Resources Saike Pharmaceutical Co., Ltd. were compared with Ezetrol ® (reference preparation, R, 10mg / tablet) produced by MSD Pharma (Singapore) Pte. Ltd. to evaluate the bioequivalence of single dose in healthy subjects under fasting and fed conditions.

Conditions

Interventions

TypeNameDescription
DRUGezetimibe tabletsThe subjects randomly received single oral administration of ezetimibe tablets 10 mg.
DRUGezetimibe tablets(Ezetrol ®)The subjects randomly received single oral administration of ezetimibe tablets 10 mg.

Timeline

Start date
2021-03-13
Primary completion
2021-06-30
Completion
2021-07-31
First posted
2021-03-24
Last updated
2021-03-24

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04814589. Inclusion in this directory is not an endorsement.

Bioequivalence of Ezetimibe Tablets in Healthy Subjects (NCT04814589) · Clinical Trials Directory